Compassionate Use Policy

Curis believes that well-designed clinical trials are the best way to determine the safety and effectiveness of investigational therapies. For studies now enrolling at Curis click here.

However, we understand that some patients may not be eligible to enroll in a clinical trial.  If you are a patient with questions regarding early access to an investigational product, you should consult with the physician who is treating your cancer. Any request for access to an unapproved product being investigated by Curis should come from your physician through an email request to ExpandedAccess@Curis.com. We will evaluate each request and respond within 5 business days.

Curis uses the following criteria for considering requests to provide access to individual patients for expanded access:

• The patient has a serious or life-threatening illness or condition
• The patient has exhausted all available treatment options
• Treatment will be administered in the United States
• Curis believes it is highly likely that the patient will experience a clinically significant benefit based on the patient’s clinical status and disease characteristics
• There are clinical data that support the possibility that the potential benefits of administration of the investigational medicinal product to the patient could outweigh the potential risks
• The investigational drug is in active clinical development with sufficient data available to determine an appropriate dose and schedule for the patient’s specific condition
• Making the investigational drug available will not negatively impact or delay the conduct of clinical trials or regulatory review or approval of the investigational drug for broader patient access
• Adequate supply of the investigational drug is available